June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...
Please provide your email address to receive an email when new articles are posted on . The switch to an infliximab biosimilar was successful in 63.5% of clinically stable patients. Most patients who ...
Please provide your email address to receive an email when new articles are posted on . SEATTLE — Patients with proliferative vitreoretinopathy experienced improved visual acuity after receiving an ...
A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous ...
Crohn’s Disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with relapsing and remitting episodes. It is a disease that progresses over time, leading to complications such as ...
NEW YORK (Reuters) - Crohn's disease patients taking Johnson & Johnson's Remicade either alone or with azathioprine experienced steroid-free remission in significantly greater numbers than those ...
Avsola (infliximab-axxq) is a brand-name IV infusion that’s prescribed for certain autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and psoriasis. As with other drugs, Avsola ...
Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results